Pertuzumab, first FDA-approved in 2012, targets ECD II on the HER2 receptor, and can act synergistically with trastuzumab by preventing the heterodimerization of HER2 with other HER receptors such as HER3, resulting in further inhibition of downstream tumor signaling [61]. The gene discussed is ERBB2; the disease is neoplasm.